

NATIONAL MALARIA CONTROL PROGRAM





Malaria Vaccine introduction and Scale up.

An overview of technical guidance to sub-national ,operational teams

Weekly NMED CME

Date:09 th July , 2024



1: Introduction

2: R21Matrix-M characteristics

3.The Malaria Vaccine schedule.

4.Data Managemenet, communication and AEFIS' surveillance

5.Malaria Vaccine Introduction plan –Brief summary



INTRODUCTION

Background.

Malaria Vaccine product information.

Malaria Vaccine mechanism of action.





Introduction:-Background

- In 2021(Oct) WHO recommended the vaccine for prevention of Falciparum in Children.
- □ Two(2) vaccines are so far WHO recommended and pre-qualified:
 - RTS,SA01 (Recommended in Oct- 2021 & prequalified July 2022).
 - R21-Matrix M(recommended in Oct- 2023 & prequalified Dec- 2023).
- No known cross protection for other Plasmodium species& are not designed for transmission interruption.
- Both are indicated for burden reduction, countries are guided to prioritize moderate to high transmission areas.
 - Prevent infection,illiness and death.
- RTS,S-Phase 3 trials (2009-2014) in various transmissions including the vary highly seasonal at 11 sites with 4-7 years of follow up.
 - Phase -3 trial for seasonal vaccination with/without chemoprevention at 2 sites in Africa with 5 years of follow-up.
 - Since 2019 16M doses have been given 2M children through a pilot implementation in Kenya, Ghana& Malawi.
- R21-Matrix-M-Phase 3 trials on since 2021 and by Oct- 2022 the only available data was for :
 - \circ Follow up of 18 months for moderate –low transmission ,highly seasonal areas.
- □ By early 2024 -8 countries were ready to introduce the Vaccine
 - Uganda plans to introduce the R21-Matrix-M to 90-105 districts starting April 2025.

Vaccine product information	
RTS,SA01	R21-MATRIX-M
 Four(4) doses given monuny from 5 monuns or age and a 4th dose provided to prolong protection. A fifth dose may be considered in cases of significant Malaria risk persisting 1 year after 4th dose. 	 Four(4) doses given montniy from 5 months of age and a 4th dose provided to prolong protection. A fifth dose may be considered in cases of significant Malaria risk persisting 1 year after 4th dose
 Two vials clipped together, reconstituted for 2 doses. 2 to .8 degrees centigrade,36 months shelf life. 9.92 sq cms per dose in secondary packaging. 	 Single dose vial(liquid)1-2 doses per vial. 2.8 degrees centigrade,24 months shelf life 7.03 sq cms per dose ,14.06sq cms in secondary packaging depending on the dose
 US\$10.00 per dose 	 US\$3.90 per dose
 GSK Belgium 	 Serum Institute of India Pvt LTD
 Good safety profile, has a data base of 6M children. The only side effects include Pain at the site of injection . Fever Febrile convulsions are associated but rare 	 Good safety profile, phase 3 trial on going among 4000 children. The only side effects include Pain at the site of injection . Fever Febrile convulsions are associated but rare
 Intramuscular injection Thigh(6-12 months) Deltoid (>12months 	 Intramuscular injection Thigh(6-12 months) Deltoid (>12months
Wastage:(7%)Buffer:(25%)	Wastage(7%)Buffer(25%
 I8 M doses available for the next 3 years;4 in 2024,6 in 2025 and 8 in 2026 for all eligible countries. 	 To make available 100M -200m doses available per year for all eligible countries.
	RTS,SA01 • Four(4) doses given mommy from 5 momms or age and a 4th dose provided to prolong protection. • A fifth dose may be considered in cases of significant Malaria risk persisting 1 year after 4th dose. • Two vials clipped together, reconstituted for 2 doses. • 2 to .8 degrees centigrade,36 months shelf life. • 9.92 sq cms per dose in secondary packaging. • US\$10.00 per dose • Good safety profile, has a data base of 6M children. • The only side effects include • Pain at the site of injection . • Fever • Febrile convulsions are associated but rare

 \bigcirc

Chase Malaria

 \bullet

How the Vaccine prevents severe forms of Malaria & death.

Life-cycle of the malaria parasite

The cycle begins when highly mobile 'sporozoites' are transferred from mosquito to human, when the mosquito bites.

The sporozoites travel to the liver, where they infect liver cells, multiply and mature into 'merozoites'. The current malaria vaccines are designed to block infection at this stage – before the parasites grow out of control.


(3)

The merozoites leave the liver and infect red blood cells, where they continue to grow and multiply, destroying the red blood cells and infecting others.

 $(\underline{4})$

Some merozoites eventually develop into sexual forms of the parasite called 'gametocytes'. When another mosquito bites, they enter its gut and reproduce, producing new sporozoites.

These migrate to the mosquito's salivary glands, and the cycle begins again.



- The Malaria Vaccine through the Circumsporozoite protein ,an antigen produced Plasmodium Falciparum stimulates the production of antibodies.
- The antibodies prevent the infection of liver cells by the sporozoites and destroy liver cells that are already infected by sporozoites.
- This interrupts progression of disease to severe Malaria forms and prevents death.



2



(preferred country option)

Vaccine composition

Storage Conditions

Administration

Contraindications

R21-Matrix M Vaccine characteristics, storage conditions and administration



Two(2) dose vial

- R21 malaria vaccine (also known as R21/Matrix-M), is a subunit recombinant protein vaccine.
 - To prevent malaria, specifically *P. falciparum* malaria, which is the most common and dangerous form of malaria .
- 2-dose vial (1 mL of 0.5mL/dose) liquid
 - no reconstitution needed
 - no preservative open vials to be discarded 6 hours after opening or at end of immunization session, whichever comes first.


(0)

R21/Matrix- M is of the subunit type, pre-erythrocytic recombinant, protein based vaccine.

- By subunit comprise of an antigen from the disease causing agent(Circumsporozoite protein –CSP).
- Recombinant –the CSP is combined with the Hepatitis –B surface antigen.
- Vaccine is made up of the R21 and Matrix-M a Saponin derived adjuvant.
- Pre-erythrocytic-acts at the liver stage of the Malaria cycle.
- □ It is an injectable vaccine given intramuscularly.
- The vaccine should be discarded 6 hours after opening OR at the end of a vaccination session.
- □ R21 malaria vaccine is freeze sensitive and light sensitive.
 - Vaccine vials should be stored in a refrigerator between +2°C and +8°C.
 - Do not open the refrigerator door often .
 - Regularly monitor the temperature of refrigerator.
 - When using coolant packs in cold boxes and vaccine carriers, they should be conditioned to reduce the risk of vaccine freezing.
- Those with VVMs & short expiry should be at the front of the refrigerator & should be used first.



Storage Conditions:



Open Vial Policy- 2 dose vial without preservatives.

 $(\bigcirc$

 $\,\circ\,$ Should be discarded within 6 hours after opening or at the end of the vaccination session

Malaria Vaccine administration –critical steps

End of the session(after the Before children arrive for Vaccination At the Immunization session. children leave) Great the care giver. Take the vials out of the Complete the tally Verify child's name and register sheet to document refrigerator. them. number of doses given. Check the home based record Check expiry date, status for: of VVM and colour of the Return unopened Vaccine, 0 liquid in the vial. Vitamin A supplementation, vaccine vials to the 0 Growth monitoring, 0 refrigerator. Other preventive services. 0 Collect and arrange Inform the care giver. supplies, tools for that.

- Ensure that the AEFI is available
- Prepare the vaccine .
- Use the thigh(6-12months)& upper arm(> 12 months).
- Share date of next dose and remind caretaker to complete the 4 doses.
- Return Home Based Record & explain potential Side effects.

- Check the carriers for open vials with unutilised doses and discard them.
- Keep the safety box in a safe and dry place.





Contraindications to the Malaria Vaccine

Malaria vaccine is <u>not recommended</u> for a child who has known severe hypersensitivity:


- To a previous dose of malaria vaccines.
- To a previous dose of Hepatitis B vaccines .
- To any of these vaccine components.

 \bigcirc

- □ A minor illness including respiratory tract infections , mild diarrhea and fever below 38.5°C is not a contraindication.
- Malnourished or HIV positive infants may be vaccinated with Malaria Vaccine using the recommended schedule.







The adapted country schedule

Addressing late turn-ups



Malaria Vaccination –schedule adapted by Uganda														
Child Age Vaccine/1	Birth	6 wks	10 wks	14 wks	5 mos	e mos	7 mos	8 mos	9 mos	12 mos	15 mo	18 mos	24 mos	
BCG	1													
Oral polio	0	1	2	3										
Нер-В	0													
DTP-HepB-Hib (penta)		1	2	3										
Pneumococcal conj.		1	2	B										
Rotavirus		1	2											
Inactivated Polio		1		2										
Meningococcal A conj.												1		
Measles-Rubella									1			2		
Yellow Fever									1					
Malaria						1	2	3				4		
Vitamin A						1				2		ß	4	
Growth Monitoring	•	•	•	•	•	•	•	•	•	•	•	•	•	
De-worming										1			2	
ITN distribution		•												
PMC (formerly IPTi)			1	2					3					

• Explain if the visit is new/lone visit or combined with existing visits for either vaccination or other interventions.

Additional visits that come along with the introduction of the vaccine provide an opportunity to track & address missed vaccinations, due health services.

It is an additional chance for giving reminders on up-coming vaccination, provide messages for net use and early treatment seeking.

Addressing late Vaccination turn -ups

- If the child misses the Malaria Vaccine for any reason, late vaccination should Happen.
- The interrupted Vaccination schedule should be resumed without necessarily repeating the previously given doses.
- A minimum of 4 weeks must be maintained between MV doses, no matter which MV dose.
- There is no upper age limit for malaria vaccine administration [country to update based on policy]

- Children aged 6- 12 months can receive the Malaria Vaccine dose 1.
- Once Vaccination starts ,children up to 5 years of age should complete their Malaria Vaccine 4 dose schedule.
- In cases of late Vaccination the next dose should be provided within the next 4 weeks





Data Management, communication & AEFIs' surveillance

Data management

Communication

AEFIs' surveillance





Communicating with care givers about the Malaria Vaccine

Chase Malaria

 $(\mathbf{0})$

- Take time to interact with caregivers before, during, and after vaccination.
- Be respectful Listen to caregivers' concerns and respond with empathy.
- "Triple A" communication (Advise, Alert and Arrange) helps to convey the correct messages on the vaccine as part of a malaria prevention strategy.
- Motivational interviewing can be used to understand reasons for delayed acceptance and to promote vaccine uptake. Your recommendation matters!

- The malaria vaccine is safe and reduces severe malaria
- 4 malaria vaccine doses provide the best protection
 - Specifically mention the 4th dose is given at [18] months of age
- Visit monthly to have their child
 - \circ $\,$ weighed and examined.
 - o receive all needed vaccines and child health services
- Some common side effects include fever and injection site pain and swelling, but these are typically short in duration
 - Report to the nearest health facility should there be any concerns following vaccination
- Even after vaccination, a child can still become sick with malaria:
 - seek prompt diagnosis and treatment for a child with fever.
 - Continuous use of existing Malaria prevention services should be emphasized.
 - LLINs(every night, IRS, IPTp, LSM, SMC

Recording and reporting Malaria Vaccine data.

All existing routine immunization HMIS tools ,data sets and indicators are already updated to include the Malaria Vaccine;

- The tools include:
 - $\circ~$ The home based record.
 - \circ Register.
 - \circ Tally sheet monthly report

□ In case of late vaccination tools to document children > 2 years will be catered for.

 \square Fill in the home-based record with the vaccines that have been administered .

- Children should begin vaccination/receive the 1st dose from 6 months of age and the 4th dose by 18 months.
- □ It is important that records utilized to:
 - Follow-up with children who have not returned for vaccinations: reminder cards, SMS/text, phone calls, community volunteers
 - Use enhanced methods to increase schedule awareness and coverage, such as announcements and linkages with other health services, particularly in the second year of life and beyond

The DHIS-2 is already customized to capture Malaria Vaccine information/data.

(0)




Monitoring of adverse events following Immunization (AEFI):

- □ AEFI : Untoward medical occurrence that follows immunization.
 - Does not necessarily have a causal relationship with the use of the vaccine or vaccine process
- Note: AEFIs (related to the vaccine or not)
 - Must be expected.
 - Can happen independent of the health worker's action.
- They must be promptly & vigilantly investigated in order to maintain confidence in the immunization programme.
- The malaria vaccine is safe and well tolerated
 - Commonly reported AEFI are:
 - O fever
 - o irritability
 - \circ pain and swelling at injection site
 - (these are typically short in duration)
 - An uncommon AEFI is febrile convulsions

- Any adverse event should be reported immediately;
 - Reporter should only report and NOT assess causality
 - Complete the standard AEFI reporting form and send to supervisor immediately for information and decision making.
- Caregivers are to report to the nearest health facility should there be any concerns following vaccination.
 - Even after vaccination, a child can still become sick with malaria: promptly seek diagnosis and treatment for a child with fever
- As a vaccinator, do not speak to the media about an AEFI
 - Refer to your supervisor who will know the identified spokespersons.
 - If you hear concerns or rumors alert your supervisor .



The AEFIs surveillance cycle and key players:



 \bigcirc



5 Malaria Vaccine Introduction plan-brief summary

Malaria Vaccine Introduction Priority Districts

Country Vaccine need

Malaria Vaccine introduction plan timelines








Malaria Vaccine Introduction – subnational prioritization





As is the WHO guidance, vaccine introduction will prioritise the moderate to high transmission 105 districts based on 2022 DHIS2 Malaria Incidence data.

The tai	geted 14 r	regions and 105 Districts
Region	Number of Districts	Districts
West Nile	13	Arua,AruaCity,Adjumani,Koboko,Madiokolo,Maracha,Moyo,Nebbi,Obongi,Pakwach Terego, Yumbe and Zombo
Acholi	09	Pader, Omoro, Nwoya. Lamwo, Kitgum, Gulu, Gulu City, Amuru and Agago
Lango	08	Oyam, Otuke, Lira City, Lira, Kwania, Kole, Amolatar and Alebtong
Karamoja	08	Moroto, Napak, Nakapiripiriti, Nabilatuk, Abim, Kotido,Karenga and Kaboongo
Teso	10	Soroti,Kumi,Bukedea,Ngora,Serere,Amuria,Kalaki, Katakwi,Kaberamaido and Kaperebyongo
Bugisu,Sebei and Bukedi	11	Tororo,Kibuku,Busia,Paliisa,Butebo, Butaleja, Budaka, Sironko, Mbale, Mbale-City,Manafwa ,
Busoga	11	Jinja, Iganga,Kaliro Luuka,Mayuge, Bugiri,Bugweri,Namutumba,Kamuli, Buyende.
North central	06	Buikwe,Kayunga,Kiboga,Luwero, Mityana,Mukono and Nakasongola
South Central	09	Bukomansimbi,Butambala,Gomba,Kalungu,Lwengo,Lyantonde,Masaka,Rakaiand Ssembabule
Bunyoro	03	Kiryandongo,Kikuube and Buliisa
Rwenzori	05	Kyegegwa,Kitagwenda, kasese, Kamwenge and ,Bundibugyo
Ankole-Kigezi	06	Ibanda ,Isingiro,Kazo, Kiruhura,Rubirizi and Kanungu

×	Vaccine ne	eds at 100%									
Year	Category	Total target population	Doses in Schedule	Vaccines Need							
2024	Moderate to Very High*	1,327,091	4	3,640,407							
2025	Moderate to Very High*	1,362,393	3 4	5,011,031							
2026	Moderate to Very High*	1,397,814	4	6,124,830							
	Vaccine needs adjusted to the r Adjustment Percentage(%)		85%	85%							
	Year		2024	2025							
Рор	oulation in the target age cohort (#)		1,327,091	1,362,393							
Population in	scope(adjusted to the set percentag	e(85%)#	1,128,027	1,158,034							
Final Vac	cine allocation(with wastage and buf	fer)	3,002,008	4,122,799							

60

-

MALARIA VACCINE INTRODUCTION PLAN -TIMELINES

X	MALARIA VACCINE INTRODUCTION PLAN -TIMELINES																			
9	Activity	Dec	Jan	Feb	Mar	April	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	April	May	Jun
1	National Level Coordination meetings																			
2	Approval of scale up application																			
3	Develop & pretesting IEC materials																			
4	Communication, advocacy on media, social media, talk shows, press briefs																			
5	Orientation of CBOs, CSOs, journalists, FBOs, private sector and professional bodies to create demand, improve access and reduce missed opportunities	ļ																		
6	Print and distribute training materials, IEC materials, HMIS tools, AEFI case investigation forms etc) by NMS																			
7	Develop training material, flip charts, and review of tools																			
8	Funds receipt in the country																			
9	Readiness assessment and verification of the cold chain inventory																			
10	Funds disbursement to district																			
11	Distribution of vaccines and related logistics																			
12	Conduct a cascade training of service providers and at national, regional and district level																			
_13	Distribution of logistics and cold chain maintenance to health facilities																			
14	Mentorship and supervision by MOH and partners																			
15	National Launch																			
16	Implementation																			
17	17 Post introduction supportive supervision																			
18 National stakeholders feedback meeting																				
Cole		tatus																		
		n Track	it not vo	t on tra	-k															
	Started but not yet on track Not started																			



Key take home messages

The vaccine is to complement other Malaria control interventions.

- Consistent ,correct use of the following preventive measures should be maintained.
 - Use of Insecticide treated nets every night.
 - Seasonal Malaria Chemoprevention
 - Intermittent Preventive treatment in Pregnancy.
 - Indoor Residual Spraying
- Prompt diagnosis and treatment remains a must even among children that have received the vaccine,
- The vaccine will be provided through routine immunization.
 - Static clinics at the Health Facility & community outreaches.
- ❑ The vaccine is safe and effective

Already being Used in countries like Kenya, Malawi ,Ghana , Cameroon ,Burkina Faso etc



End ,thank you and questions



